Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Chemotherapy.

The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Houston, Texas
Treatments:ChemotherapyHospital:The University of Texas M. D. Anderson Cancer Center
Drugs:Journal:Link
Date:Aug 2009

Description:

Patients:
This phase II study involved 119 non-Hodgkin’s lymphoma patients with a median age of 60 years; 54% were male.

Treatment:
Patients were treated a drug called Marqibo, which is a formulation of the chemotherapy agent vincristine.

Toxicities:
The most severe toxicities were of grade 4 and included shortness of breath, neurotoxicity, neutropenia, and anemia.

Results:
The median overall survival was 6.9 months.

Support:
Some of the authors were employed by Hana Biosciences, makers of Marqibo.

Correspondence: Dr. M. A. Rodriguez; email: [email protected]



Back